Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel drug candidates for immuno-inflammatory diseases. The company leverages its proprietary KINect® drug discovery platform to translate scientific discoveries into therapeutic solutions for underserved conditions. Its headquarters are located in Wayne, Pennsylvania.

Aclaris Therapeutics maintains a multi-stage portfolio of drug candidates, encompassing both oral kinase inhibitors and biologic therapies. Key investigational product candidates include Bosakitug (ATI-045), ATI-2138 (an ITK/JAK3 inhibitor), ATI-052 (an anti-TSLP/IL-4Rα bispecific antibody), ATI-9494, and Lepzacitinib (ATI-1777). The company's focus is on immuno-inflammatory diseases, particularly those affecting the skin. Additionally, Aclaris operates Confluence Discovery Technologies, Inc., a contract research organization providing drug discovery and early development services.

Recent notable developments include positive full top-line Phase 1a results for ATI-052 in April 2026, indicating a favorable safety, pharmacokinetic, and pharmacodynamic profile that supports infrequent dosing. Concurrently, Aclaris announced lichen planus as the lead indication for its oral ITK/JAK3 inhibitor, ATI-2138, with plans to initiate a Phase 2b basket study in the second half of 2026, targeting a potential U.S. market opportunity of $1.0 billion to $4.0 billion. Dr. Neal Walker serves as the Chief Executive Officer and Chair of the Board of Directors, with Hugh Davis, PhD, as Director, President, and Chief Operating Officer.